# IPG1094 Phase I Study for China Healthy Participants

> **NCT07679113** · PHASE1 · RECRUITING · sponsor: **Nanjing Immunophage Biotech Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** IPG1094 Tablets

## Key facts

- **NCT ID:** NCT07679113
- **Lead sponsor:** Nanjing Immunophage Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2027-01-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679113, "IPG1094 Phase I Study for China Healthy Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07679113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*